RE: ENDO IR clarification
We must also remember the responsibilities of the Committee, one of which being - at each reunion - to determine if there is sufficient basis to continue the trial (vs efficacy).
The trial started in 2006 so many (or most) patients are in the maintenance phase - and data continue to accumulate over the 1 year primary endpoint (disease free survival rate after 1 year)
This probably complicate the analysis.